title: Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.
authors: National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology & Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, China.
authors: X
authors: X
authors: Niu
authors: 1] National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology & Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, China [2] Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA.
authors: G
authors: G
authors: Wang
authors: Department of Pediatric Hematology and Oncology, The First Hospital of Jilin University, Changchun, China.
authors: Y
authors: Y
authors: Wang
authors: 1] Wayne State University School of Medicine, Detroit, MI, USA [2] Cancer Biology Graduate Program, Wayne State School of Medicine, Detroit, MI, USA.
authors: J T
authors: JT
authors: Caldwell
authors: 1] Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA [2] Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
authors: H
authors: H
authors: Edwards
authors: 1] National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology & Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, China [2] Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA [3] Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
authors: C
authors: C
authors: Xie
authors: 1] Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA [2] Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA [3] Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI, USA.
authors: J W
authors: JW
authors: Taub
authors: Department of Pediatric Hematology and Oncology, The First Hospital of Jilin University, Changchun, China.
authors: C
authors: C
authors: Li
authors: Department of Hematology and Oncology, The First Hospital of Jilin University, Changchun, China.
authors: H
authors: H
authors: Lin
authors: 1] National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology & Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, China [2] Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA [3] Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
authors: Y
authors: Y
authors: Ge
mesh_terms: D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010641:Phenotype; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D015514:Oncogene Proteins, Fusion; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; D051788:Myeloid-Lymphoid Leukemia Protein; C579720:venetoclax